Are you living with chronic kidney disease?

If you are at least 18 years of age and referred for arteriovenous fistula creation surgery, you may be eligible for the SAVE-FistulaS clinical trial

Standard of Care

Arteriovenous fistulas are the standard of care in hemodialysis. Unfortunately, they have a 50 - 60% 1-year failure rate, resulting in catheter reliance, interventions, and many other complications that adversely impact patients.

Our Goal

At VenoStent, we are working to improve the usability and durability of AVFs for more reliable dialysis. This could have a positive impact on patient care and quality of life for chronic kidney disease (CKD) patients.

Remuneration

If you are eligible for this trial and elect to participate, you will be compensated for your participation. Ask your doctor for more details.

Latest Updates

Mar 14, 2024Thank you and congratulations to Shouwen Wang, MD, PhD, FASN and the fantastic team at the Arizona Kidney Disease & Hypertension Center for their first randomization in the SAVE-FistulaS Clinical Trial!

Mar 5, 2024A huge thank you and congratulations to the Medical University of South Carolina, Mark J. London, MD, and Faren M. Stroman, NP for their first randomization in the SAVE-FistulaS clinical trial!

Feb 9, 2024A big congratulations and thank you to Dr. Ryan Turley, Shir Yelovitch, Delicia Valentin and the team at Cardiothoracic and Vascular Surgeons of Central Texas for their first randomization in the SAVE-FistulaS Clinical Trial!

See all updates

clinicaltrials.gov: NCT06001827

SelfWrap is currently in the research and development phase and is not available for sale in any country. Investigational device. Limited by federal law to investigational use.